SCHEMBL17099274

SCHEMBL17099274

C=Cc1nccc(Br)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31178337 1.00
SCHEMBL25404242 0.77
SCHEMBL872419 0.74 HDAC8 (0.33)
SCHEMBL28492128 0.73
SCHEMBL12805217 0.73
SCHEMBL9159764 0.73
SCHEMBL4024375 0.73
SCHEMBL6887027 0.73
SCHEMBL8270697 0.73
SCHEMBL16803989 0.72 CHRNA7 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109053723-A Sulfamide derivative and its medicinal usage EA制药株式会社 2018-12-21 CN disclosed
US-9828409-B2 Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides ZHONG MINGHONG (US) 2017-11-28 US disclosed
US-20150266918-A1 Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides ZHONG MINGHONG (US) 2015-09-24 US disclosed
CN-104302645-A Antibacterial compounds BIOTA EUROPE LTD 2015-01-21 CN disclosed
CN-101039904-B Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders ABBOTT GMBH & CO KG 2014-09-24 CN disclosed